Year: 2020

Recon takes an analytical look behind select developments in healthcare

Strategy in the Time of Covid

Nikhil Bhojwani April 15, 2020

Preamble A recent post from Recon Strategy outlined the longer-term strategic implications of Covid-19 on 12 healthcare sectors. This post highlights the opportunity to redeploy corporate strategy assets to focus on the most important short-term strategy imperatives to not only ensure organizational resilience but to set up for success coming out of this crisis. Corporate strategy teams have tremendous analytical, creative, and operationally savvy resources that are accustomed to jumping into new situations, getting quickly up-to-speed, and delivering value. Leaders should proactively point these resources towards these areas of greatest

The day after: Implications for hospitals, payers, biotech and more…

Nikhil Bhojwani April 6, 2020

Even as our priority today is dealing with the Covid crisis, healthcare organizations would do well to start thinking about the longer-term implications for their strategies. In some instances the marketplace will revert to the prior dynamic, but in many others the changes wrought during this crisis are likely to persist in a way that will call for new strategy or will produce unpredictable outcomes that will require scenario planning. Sectors will be impacted in very different ways and there will be winners and losers in each. In this short

The infectiologists have the floor: An opinionated take on NEJM highlights for March 2020

Marc Herant March 31, 2020

A first Covid-19 interventional study – unfortunately negative The first of what promises to be a series of many interventional studies for acute Covid-19 disease to appear in the Journal. Lopinavir is an HIV drug that had shown in-vitro activity against SARS, another corona virus, and ritonavir is a drug that boosts lopinavir concentration by reducing its rate of metabolization – so it was worth trying the combo in sick patients with Covid-19. The study was clearly conducted in quasi-battlefield conditions in one of Wuhan’s main hospital from mid-January to

Coronavirus and more: An opinionated take on NEJM highlights for January/February 2020

Marc Herant March 2, 2020

Keeping up with COVID-19 It’s not easy for a refereed weekly print periodical to keep up with an epidemic that evolves on a daily basis, but the NEJM is doing its best and all articles are free on-line. Most interesting beyond the description of the initial cluster in Wuhan are: (1) the first US case was quite severe and the patient received the antiviral remdesivir (was in development by Gilead for Ebola, but showing activity against coronaviruses) – it is now in testing in China; (2) the rigorous documentation of

Tax dollars doing good work: An opinionated take on NEJM highlights for December 2019

Marc Herant January 5, 2020

The loneliness of the patent-less drug Colchicine is a very old drug commonly used in gout with an anti-inflammatory mechanism of action that is not well defined. It is a generic (although in the US, the story is somewhat peculiar) and therefore incentives are lacking for further development in new indications by private companies. Given a well-established (but not well-understood) connection between inflammation and cardiovascular events, some researchers have hypothesized and explored potential utility in patients with high cardiovascular risk – but this would have to be validated by a

Year: 2020

Recon takes an analytical look behind select developments in healthcare

Strategy in the Time of Covid

The day after: Implications for hospitals, payers, biotech and more…

The infectiologists have the floor: An opinionated take on NEJM highlights for March 2020

Coronavirus and more: An opinionated take on NEJM highlights for January/February 2020

Tax dollars doing good work: An opinionated take on NEJM highlights for December 2019

SUBSCRIBE

Categories

Authors

Archives